Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study - Wikidata - awgldk - TriplyDB

Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study

Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study

http://www.wikidata.org/entity/Q33495790

about

Sorafenib inhibits epithelial-mesenchymal transition through an epigenetic-based mechanism in human lung epithelial cells BCRP/ABCG2 inhibition sensitizes hepatocellular carcinoma cells to sorafenib Sorafenib-resistant hepatocellular carcinoma stratified by phosphorylated ERK activates PD-1 immune checkpoint Predicting the response to sorafenib in hepatocellular carcinoma: where is the evidence for phosphorylated extracellular signaling-regulated kinase (pERK)?New knowledge of the mechanisms of sorafenib resistance in liver cancer A multidisciplinary approach to the management of hepatocellular carcinoma.YLT192, a novel, orally active bioavailable inhibitor of VEGFR2 signaling with potent antiangiogenic activity and antitumor efficacy in preclinical models ERK1/2 deactivation enhances cytoplasmic Nur77 expression level and improves the apoptotic effect of fenretinide in human liver cancer cells Role of anti-angiogenesis therapy in the management of hepatocellular carcinoma: The jury is still out.Schedule-dependent antitumor effects of 5-fluorouracil combined with sorafenib in hepatocellular carcinoma PHY906(KD018), an adjuvant based on a 1800-year-old Chinese medicine, enhanced the anti-tumor activity of Sorafenib by changing the tumor microenvironment.Extracellular signal-regulated kinase 1 and 2 in cancer therapy: a focus on hepatocellular carcinoma.Liposome-mediated RNA interference delivery against Erk1 and Erk2 does not equally promote chemosensitivity in human hepatocellular carcinoma cell line HepG2.Sorafenib, a multikinase inhibitor, is effective in vitro against non-Hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin.The sum of gains and losses of genes encoding the protein tyrosine kinase targets predicts response to multi-kinase inhibitor treatment: Characterization, validation, and prognostic value.Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells.pERK/pAkt phenotyping in circulating tumor cells as a biomarker for sorafenib efficacy in patients with advanced hepatocellular carcinoma.Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma Practical effect of sorafenib monotherapy on advanced hepatocellular carcinoma and portal vein tumor thrombosis Impact of restricting access to high-cost medications for hepatocellular carcinoma.Hepatocellular carcinoma: systemic therapies and future perspectives.A 4-Phenoxyphenol Derivative Exerts Inhibitory Effects on Human Hepatocellular Carcinoma Cells through Regulating Autophagy and Apoptosis Accompanied by Downregulating α-Tubulin Expression.Initial analysis of peripheral lymphocytic extracellular signal related kinase activation in autism.Use of VEGFR-2 targeted ultrasound contrast agent for the early evaluation of response to sorafenib in a mouse model of hepatocellular carcinoma.The Ras/Raf/MEK/ERK signaling pathway and its role in the occurrence and development of HCC.Sorafenib off-target effects predict outcomes in patients treated for hepatocellular carcinoma.Tivantinib: a new promising mesenchymal-epithelial transition factor inhibitor in the treatment of hepatocellular carcinoma.An investigation of the effect of sorafenib on tumour growth and recurrence after liver cancer resection in nude mice independent of phosphorylated extracellular signal-regulated kinase levels.Bufalin enhances the anti-proliferative effect of sorafenib on human hepatocellular carcinoma cells through downregulation of ERK.Stimulatory effects of the multi-kinase inhibitor sorafenib on human bladder cancer cells MAT2B-GIT1 interplay activates MEK1/ERK 1 and 2 to induce growth in human liver and colon cancer.Expression of pERK and VEGFR-2 in advanced hepatocellular carcinoma and resistance to sorafenib treatment.Endothelial progenitor cell number and ERK phosphorylation serve as predictive and prognostic biomarkers in advanced hepatocellular carcinoma patients treated with sorafenib.Biomarkers and Personalized Sorafenib Therapy.MEK inhibition induced downregulation of MRP1 and MRP3 expression in experimental hepatocellular carcinoma.Reversing multidrug resistance in hepatocellular carcinoma cells by inhibiting extracellular signal-regulated kinase/mitogen-activated protein kinase signaling pathway activity.Rapid regression of advanced hepatocellular carcinoma associated with elevation of des-gamma-carboxy prothrombin after short-term treatment with sorafenib - a report of two cases.Guideline on the use of new anticancer drugs for the treatment of Hepatocellular Carcinoma 2010 update.Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.Sorafenib delays recurrence and metastasis after liver transplantation in a rat model of hepatocellular carcinoma with high expression of phosphorylated extracellular signal-regulated kinase.

P2860

Q28533484-B8620146-B037-412A-B8A3-37E6CB2DB343 Q28538126-61CF6A6C-160D-4E7D-B9DF-BC3617E5B041 Q28816970-7A5783ED-C6B8-4735-A62D-C752CB613A63 Q33496309-021431BA-016E-452B-8621-B6ECB27F9256 Q33759933-C391DD9E-8371-4A70-858B-8AE1B1D06F91 Q33916361-7F77B9A1-CF03-4084-A362-177B98E6358D Q34030791-0E12401A-E0B6-471F-AF49-0463B502E152 Q34687273-B5951AB7-B614-4F34-B63E-6D5530F289EC Q34728237-8C4FEC80-BC35-47F6-BAD2-E015A0987985 Q34877852-6FB72362-F74A-4537-87A4-B89E222889F6 Q35227285-1310B953-50F4-49A2-A6C6-CF280858752F Q35894374-BC07A736-B177-438C-8122-918E1E800FDC Q36241772-7D368721-B5DC-4F13-8AD4-0366CDD8C6F5 Q36301590-E379C886-AAA5-4AD2-9677-D3B63741E383 Q36413467-02998A20-048C-4381-A2E0-72419087A2FF Q36560547-835A12FC-F037-40FC-92F8-24992617A877 Q36771900-09CE5800-57B5-4C65-A6FB-6141C289A159 Q37049104-2430825C-045A-4958-8B73-51C1663524C9 Q37359379-7FED372B-E9DE-48C4-BFEF-AFC387FB9537 Q38042711-934775E5-C908-42FD-922F-9DF9AEE8250F Q38246965-8A1698FC-5F4B-465D-BC60-310108C37551 Q38680790-857F6737-42FE-40E9-A9C0-C74910FF95A5 Q38811433-204EBEB6-4871-4D4C-95B0-C02404528495 Q38969661-A78CD860-646D-4770-90A0-037BDA844970 Q39023984-945207E0-F3B5-4A62-9DC9-37A06AC2701F Q39030388-0FF42690-7C86-4018-8173-018AF64B6137 Q39466467-1634DF4F-FE69-458F-8015-75EFB3682B45 Q39524844-18A09ABC-5FDE-4155-8010-5B2A2A3C5D4E Q39535341-4F871E3D-3BBC-40FA-9C86-9697BB1ADA8B Q39677393-C8300B26-E77B-4206-AAE7-2E7C169BE4DF Q40321098-D06FDB3D-CBA2-4938-A727-0A5FAC130E24 Q41563253-F597A8E7-43EF-4B64-82FD-57E8FD17644D Q41625103-59F12B36-90E1-4341-96C6-6C1B5E419174 Q41879721-5848D7E1-AB4A-4F0C-A889-5B834F176935 Q42091691-50C46AA0-07A8-4C62-98C8-FC490ED0DA76 Q42182238-88E61525-234D-4DE2-8F4A-E9837F8C8A2A Q42617374-66455106-F65D-410F-8F4C-829EC284D00E Q44079528-2E927CC2-BC95-4611-897E-B5DD08D5B556 Q45275265-75C1A4F6-F3E1-45FE-9F3F-5F1BF3CC83BE Q45952585-A485660A-2D22-4C5A-9571-EE94F5C4C965

P2860

Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study

http://www.wikidata.org/entity/Q33495790

description

2009 nî lūn-bûn

@nan

2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

name

Phosphorylated ERK is a potent ...... vidence from an in vitro study

@ast

Phosphorylated ERK is a potent ...... vidence from an in vitro study

@en

type

label

Phosphorylated ERK is a potent ...... vidence from an in vitro study

@ast

Phosphorylated ERK is a potent ...... vidence from an in vitro study

@en

prefLabel

Phosphorylated ERK is a potent ...... vidence from an in vitro study

@ast

Phosphorylated ERK is a potent ...... vidence from an in vitro study

@en

P1433

Q33495790-29EC7803-8CCE-4983-BE3C-27D0B42627BE

P1476

Q33495790-8E57BEB2-12DE-4960-8E67-19992AA6E483

P2093

Q33495790-00473E0C-53FB-4DC1-8DB8-69612E02ECD9

Q33495790-34A81C30-6765-4DD4-B237-C06E9B4FBEAB

Q33495790-952B76FE-AEFB-49A8-AFF2-F0867919A02B

Q33495790-E6B525F5-6167-483D-98FE-BCB4CA8B995D

Q33495790-FF4971F1-1DBD-4F11-9696-0DF6A6E1C34A

P2860

Q33495790-11CE12E2-98CA-4740-8824-1CBD12BA3AC7

Q33495790-2FBB7BA8-2E25-464C-B21F-1EF7D0E27078

Q33495790-30F76ACD-151B-438A-8537-B5777503AED1

Q33495790-342D8768-4656-4EBC-B5AF-1B57C006D365

Q33495790-3AF5A48A-BE5A-4C95-AD9E-6B66FBFD84EA

Q33495790-4E868CEF-750F-43F5-A44C-3504CA02E303

Q33495790-622919A4-3CF3-4BAA-82CC-8A4849BAFCC6

Q33495790-72A16B7F-62F4-4761-A0B0-A01102BABBCB

Q33495790-7DBEC7E5-B20B-446E-BF58-37EDE7F8B532

Q33495790-99F7EEBD-4291-4CAD-9D52-5539EB2A01B1

P2888

Q33495790-C39FD255-B648-4E32-B231-6D869291D6C9

P304

Q33495790-9E089AF0-317E-458A-A567-93F9DE5803E2

P31

Q33495790-45BCB855-ABD9-4518-AAE9-2360C85FA90D

P356

Q33495790-49775860-BE09-4969-8592-163D60B394E1

P407

Q33495790-53CAE315-6291-4720-BA89-3DA9ADFB2477

P478

Q33495790-82585B09-BA3A-4C46-AA55-1F474286745B

P577

Q33495790-32DA3799-1B35-4E40-80A3-7E16CDF3027A

P5875

Q33495790-F4897FB1-F88A-4D57-8836-3A2C96FD697A

P6179

Q33495790-6FF1A12B-0797-4A83-80AA-594F734CA77C

P698

Q33495790-DCA7EF10-1C94-43DB-920B-1A0CCD1A91DF

P921

Q33495790-04AE1EE6-219F-4E37-B4FD-7FD58B434F5F

P932

Q33495790-EC99EF7E-D0EF-436A-8EBB-5554ADAFE7C5

P356

P1433

P1476

Phosphorylated ERK is a potent ...... vidence from an in vitro study

@en

P2093

Dexing Wang

http://www.w3.org/2001/XMLSchema#string

Hujia Shen

http://www.w3.org/2001/XMLSchema#string

Xiaoyun Zhou

http://www.w3.org/2001/XMLSchema#string

Yanhong Wang

http://www.w3.org/2001/XMLSchema#string

Zhe Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics, 2002

Sorafenib in advanced hepatocellular carcinoma

Targeting RAS signalling pathways in cancer therapy

Hepatocellular carcinoma

Management of hepatocellular carcinoma

Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

Role of MAP kinase in tumor progression and invasion.

Angiogenesis and hepatocellular carcinoma.

P2888

P304

41

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1741-7015-7-41

http://www.w3.org/2001/XMLSchema#string

P407

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2009-08-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26758599

http://www.w3.org/2001/XMLSchema#string

P6179

1033996106

http://www.w3.org/2001/XMLSchema#string

P698

19698189

http://www.w3.org/2001/XMLSchema#string

P921

phosphorylation

P932

2738687

http://www.w3.org/2001/XMLSchema#string